Two cases decided over the last three months have added California[1] and Massachusetts[2] to the list of minority states that hold brand name manufacturers of drugs (“Brand Manufacturers”) liable under state “failure to warn” laws when sued by patients that exclusively used a generic version of the Brand Manufacturer’s drug. These cases follow the US
Latest Post
More Posts
Recent State Court Decisions and FDA Inaction Leave Brand Name Manufacturers Uncertain About Liability for Updating Safety Labeling: The Impact of the “Sameness” Standard
Medicare Secondary Payer Compliance: Payer FCA Litigation (Part VII)
Medicare Secondary Payer Compliance: Payer FCA Litigation (Part VII)
Medicare Secondary Payer Compliance: The False Claims Act (FCA) for Providers (Part VI)
Medicare Secondary Payer Compliance: The False Claims Act (FCA) for Providers (Part VI)
Medicare Secondary Payer Compliance: Providers (Part V)
Medicare Secondary Payer Compliance: Providers (Part V)
Medicare Secondary Payer Compliance: Non-Group Health Plans (NGHPs) (Part IV)
Medicare Secondary Payer Compliance: Non-Group Health Plans (NGHPs) (Part IV)
Subscribe: Subscribe via RSS
Blogs
Firm/Org